Colorectal Cancer Molecular Diagnostics Industry Valued at $3.79 Billion by 2029 With CAGR of 8.1% | Size and Share Insights
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Colorectal Cancer Molecular Diagnostics Market from 2024 to 2025?
In recent times, there has been a substantial growth in the market size for colorectal cancer molecular diagnostics. The industry is projected to increase from a value of $2.56 billion in 2024 to $2.77 billion in 2025, implying an 8.1% compound annual growth rate (CAGR). The historical growth trend can be linked to a rise in colorectal cancer cases, increased awareness and screening measures, an enhanced focus on personalized medicine, and government measures towards cancer management.
What Is the Projected Market Size of the Colorectal Cancer Molecular Diagnostics Market?
The market size of molecular diagnostics for colorectal cancer is anticipated to experience a robust increase in the forthcoming years, expanding to $3.79 billion in 2029 with a compound annual growth rate (CAGR) of 8.1%. This projected growth during the forecast period can be attributed to factors such as the aging population and heightened risk factors, the inclusion of genomic data in clinical practice, advancements in precision medicine, and worldwide collective endeavors in cancer research. Key trends in this forecast period include an intensified focus on early detection markers, the incorporation of artificial intelligence (AI) in data examination, the emergence of circulating tumor DNA (CTDNA) analysis, the broadening of companion diagnostics for targeted treatments, and a concentration on immunotherapy markers.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13120&type=smp
Who are the Major Competitors in the Colorectal Cancer Molecular Diagnostics Market Outlook?
Major companies operating in the colorectal cancer molecular diagnostics market report are Johnson & Johnson, Bayer AG, Abbott Laboratories, Danaher Corporation, Becton Dickinson and Company, Biocartis Group NV, Agilent Technologies Inc., Grifols S.A, Hologic Inc., Biomérieux SA, Quidel Corporation, Bio-Rad Laboratories Inc., Qiagen N.V., Exact Sciences Corporation, Illumina Inc., Cepheid, Myriad Genetics Inc., Guardant Health, Luminex Corporation, GenMark Diagnostics, Amoy Diagnostics Co. Ltd., MDxHealth Inc., HTG Molecular Diagnostics Inc., GenPath Diagnostics, geneOmbio Technologies Pvt.
What Is Fueling Growth in the Colorectal Cancer Molecular Diagnostics Market?
The rise in inflammatory bowel diseases (IBD) is anticipated to steer the progression of the colorectal cancer molecular diagnostics market. The chronic gastrointestinal conditions known as IBDs are distinguished by inflammation in the digestive tract and predominantly affect the colon and rectum. This inflammation leads to abdominal discomfort, diarrhea, and weight loss. Management of these symptoms requires pharmaceutical interventions, alteration of lifestyle habits, and occasionally surgery. The mounting occurrence of IBDs amplifies the need for accurate, prompt, and sophisticated diagnostic measures. These diagnostic methods form a pivotal element in determining systemic therapy for colorectal cancer (CRC), drawing mainly from the molecular assessment results of the tumor. For example, in April 2024, the UK Parliament, a UK-based governing body, revealed research from 2022 by Crohn’s & Colitis UK. This research disclosed that Inflammatory Bowel Disease (IBD) affected 500,000 UK residents, nearly two times higher than earlier approximations. Hence, an increase in inflammatory bowel diseases (IBD) is set to enhance the growth of the colorectal cancer molecular diagnostic market. A section of the colorectal cancer molecular diagnostics market report pinpointed the impact of an upsurge in colorectal cancer prevalence on the market in question. The escalating occurrence of colorectal cancer is set to fuel the progression of the colorectal cancer molecular diagnostics market. Colorectal cancer is a health condition that impairs the colon or rectum, which are key sections of the digestive system. This form of cancer comes to light when cells in the colon or rectum proliferate uncontrollably, consequently forming a malignant tumor. An upswing in colorectal cancer amplifies the necessity for molecular diagnostics that detect and treat cancer. To illustrate, the American Cancer Society, a US-based country-wide voluntary health organization on a mission to eradicate cancer, furnished information in March 2023. According to statistics, approximately 153,020 people are projected to be diagnosed with CRC (colorectal cancer), of which roughly 52,550 will likely succumb to the affliction. Among these, 19,550 cases and 3,750 fatalities are expected to be in patients younger than 50. Therefore, the rise in colorectal cancer prevalence is spurring the growth of the colorectal cancer molecular diagnostics market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=13120&type=smp
Which Colorectal Cancer Molecular Diagnostics Market Segments Are Growing the Fastest?
The colorectal cancer molecular diagnostics market covered in this report is segmented –
1) By Type: Instruments, Reagents And Kits, Services
2) By Technology: Polymerase Chain Reaction (PCR), Sequencing, Mass Spectrometry, Transcription Mediated Amplification, Chips And Microarrays, Isothermal Nucleic Acid Amplification Technology (INAAT)
3) By End Users: Hospitals, Ambulatory Surgical Centers, Diagnostic Laboratories, Homecare Settings
Subsegments:
1) By Instruments: PCR Machines, Sequencers, Microarrays
2) By Reagents And Kits: DNA Or RNA Extraction Kits, Assay Kits, Reagent Packs
3) By Services: Diagnostic Testing Services, Genetic Testing Services, Consultation Services
Which Industry Trends Are Shaping the Future of the Colorectal Cancer Molecular Diagnostics Market?
Leading businesses in the colorectal cancer molecular diagnostic market are working on the development of cutting-edge molecular diagnostics and personalized medicine solutions. Among these is the Shield Blood Test, an innovative approach targeting early detection of colorectal cancer, a stage when the disease is more manageable. This pioneering blood test was introduced by US-based biotech firm Guardant Health in May 2022. They position the Shield Blood Test as a user-friendly screening tool that resolves issues related to patient readiness for screenings owing to its simplicity- a straightforward blood draw. The test presents a 91% sensitivity rate for colorectal cancer detection, and a 20% rate for advanced adenomas identification; its specificity was pegged at 92%. The test’s ability to detect early signs of colorectal cancer in the blood is attributed to the use of information from a varied cohort of more than 2,000 colorectal cancer subjects, 357 advanced adenoma subjects, and 3,757 normal subjects.
Access The Full Report Here:
Which Countries Are Leading the Colorectal Cancer Molecular Diagnostics Market?
North America was the largest region in the colorectal cancer molecular diagnostics market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the colorectal cancer molecular diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13120
This Report Delivers Insight On:
1. How big is the colorectal cancer molecular diagnostics market, and how is it changing globally?
2. Who are the major companies in the colorectal cancer molecular diagnostics market, and how are they performing?
3. What are the key opportunities and risks in the colorectal cancer molecular diagnostics market right now?
4. Which products or customer segments are growing the most in the colorectal cancer molecular diagnostics market?
5. What factors are helping or slowing down the growth of the colorectal cancer molecular diagnostics market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
